Abstract
Adjuvant endocrine treatment for premenopausal woman remains a controversial area in the therapeutical approach of early stages of breast cancer. Metaanalysis show that ovarian ablation and suppression produce, in a global way, significant benefits in terms of reduction of the risk of recurrence and death. Nevertheless, in the presence of adjuvant chemotherapy, the benefits of ovarian suppression or ablation are clearly reduced, probably in relation to the impact that amenorrhoea induced by chemotherapy. On the other hand, in premenopausal patients, the same metaanalysis show that the use of adjuvant tamoxifen produces benefits in disease-free survival and overall survival very similar to those observed in postmenopausal women. Additionally, the benefits from tamoxifen persist independently of whether or not adjuvant chemotherapy is being received. Thus, some of the questions to answer are: first, is there, in premenopausal women, an additional benefit when ovarian suppression is associated to tamoxifen? Second, it remains controversial if ovarian suppression must be indicated for all patients who receive chemotherapy or only those that have not reached amenorrhoea when adjuvant chemotherapy is completed. Moreover, although in the last decades more than 15,000 premenopausal patients have been included in specific trials of adjuvant endocrine therapy with ovarian suppression or ablation, the best modality of treatment has not been established, and what is more important, the role of its association with tamoxifen has not been completely defined. Many of these aspects remain controversial and the decision about the best therapeutical approach must be individualised in each patient.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ruiz A, Lluch A, Martín M et al (2005) Spanish Breast Cancer Research Group (GEICAM) population-based study on breast cancer outcomes: El Álamo project (1990–1997). J Clin Oncol 23[Suppl]:585
Strasser-Weippl K, Goss PE (2005) Adjuvant endocrine therapy options in hormone-dependent breast cancer. Eur J Cancer (Suppl) 3:247
Beatson GW (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
International Breast Cancer Study Group (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol 24:1332–1341
Davidson NE, O’Neill AM, Vukov AM et al (2005) Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23:5973–5982
Kaufmann M, Jonat W, Blamey R et al (2003) Survival analyses from the ZEBRA study: goserelin (Zoladex TM) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711–1717
(1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy’s Hospital, London. Lancet 341:1293
Ejlertsen B, Dombernowsky P, Mouridsen HT et al (1999) Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor-positive breast cancer patients (abstract). Proc Am Soc Clin Oncol 18:66a
von Minckwitz G, Graf E, Geberth M et al (2004) Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial (abstract). Proc Am Soc Clin Oncol 23:11s
Wallwiener D, Possinger K, Schmid P et al (2004) A phase III trial comparing adjuvant treatment with leuprolin acetate (3M-depot) for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal breast cancer patients (abstract). Proc Am Soc Clin Oncol 22:10s
Jakesz R, Hausmaninger H, Kubista E et al (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer — Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621
Boccardo F, Rubagotti A, Amoroso D et al (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718
Roche HH, Kerbrat PP, Bonneterre J (2000) Complete hormonal blockade versus chemotherapy in premenopausal early stage breast cancer patients with positive hormone receptors and 1–3 node positive tumors: results of the FASG 06 Trial (abstract). Proc Am Soc Clin Oncol 19:72a
Roche H, Mihura J, de Lafontan B et al (1996) Castration and tamoxifen versus chemotherapy for premenopausal, node and receptors-positive breast cancer patients: a randomized trial with 7 years median follow-up (abstract). Proc Am Soc Clin Oncol 15:117a
International Breast Cancer Study Group (2003) Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95:1833–1846
Arriagada R, Le MG, Spielmann M et al (2005) Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16:389
Baum M, Hackshaw A, Houghton J et al (2006) Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 42:895–904
Parulekar WR, Day AG, Ottaway JA et al (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study — NCIC CTG MA.5. J Clin Oncol 23:6002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rodríguez Sánchez, C.A. Adjuvant endocrine therapies for premenopausal women. Clin Transl Oncol 9, 369–374 (2007). https://doi.org/10.1007/s12094-007-0069-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-007-0069-5